FY2027 EPS Estimates for Inspire Medical Systems, Inc. (NYSE:INSP) Increased by Leerink Partnrs

Inspire Medical Systems, Inc. (NYSE:INSP) – Leerink Partnrs boosted their FY2027 EPS estimates for shares of Inspire Medical Systems in a research report issued on Tuesday, May 7th. Leerink Partnrs analyst M. Kratky now forecasts that the company will post earnings per share of $4.15 for the year, up from their previous estimate of $4.13. The consensus estimate for Inspire Medical Systems’ current full-year earnings is ($0.35) per share. Leerink Partnrs also issued estimates for Inspire Medical Systems’ FY2028 earnings at $5.21 EPS.

Several other analysts also recently weighed in on the company. Truist Financial reissued a “buy” rating and set a $280.00 target price on shares of Inspire Medical Systems in a research note on Wednesday, March 20th. Royal Bank of Canada initiated coverage on shares of Inspire Medical Systems in a research note on Friday, April 19th. They issued an “outperform” rating and a $285.00 price objective for the company. Mizuho reiterated a “buy” rating and set a $250.00 target price on shares of Inspire Medical Systems in a report on Wednesday, March 27th. Jefferies Financial Group started coverage on shares of Inspire Medical Systems in a report on Friday, January 19th. They issued a “buy” rating and a $245.00 price target for the company. Finally, Morgan Stanley initiated coverage on shares of Inspire Medical Systems in a research note on Tuesday, March 19th. They set an “overweight” rating and a $250.00 price objective on the stock. Five analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $256.53.

Inspire Medical Systems Stock Down 33.0 %

INSP opened at $164.47 on Thursday. The business has a fifty day moving average of $215.68 and a 200 day moving average of $190.38. The stock has a market cap of $4.98 billion, a P/E ratio of -222.26 and a beta of 1.35. Inspire Medical Systems has a 52-week low of $123.27 and a 52-week high of $330.00.

Inspire Medical Systems (NYSE:INSP) last announced its earnings results on Tuesday, May 7th. The company reported ($0.34) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.63) by $0.29. Inspire Medical Systems had a negative return on equity of 3.93% and a negative net margin of 3.39%. The business had revenue of $164.01 million during the quarter, compared to analyst estimates of $161.41 million. During the same quarter in the previous year, the business earned ($0.53) earnings per share. The company’s revenue for the quarter was up 28.2% compared to the same quarter last year.

Insider Activity at Inspire Medical Systems

In related news, insider Randy Ban sold 3,060 shares of the company’s stock in a transaction on Tuesday, February 27th. The stock was sold at an average price of $182.01, for a total value of $556,950.60. Following the transaction, the insider now directly owns 3,029 shares of the company’s stock, valued at approximately $551,308.29. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. In other news, insider Randy Ban sold 3,060 shares of the company’s stock in a transaction on Tuesday, February 27th. The shares were sold at an average price of $182.01, for a total value of $556,950.60. Following the sale, the insider now directly owns 3,029 shares of the company’s stock, valued at approximately $551,308.29. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Jerry C. Griffin sold 554 shares of the company’s stock in a transaction dated Monday, March 11th. The stock was sold at an average price of $198.05, for a total value of $109,719.70. Following the completion of the sale, the director now owns 9,744 shares in the company, valued at approximately $1,929,799.20. The disclosure for this sale can be found here. Insiders have sold 76,371 shares of company stock valued at $15,664,278 in the last ninety days. Corporate insiders own 4.10% of the company’s stock.

Institutional Trading of Inspire Medical Systems

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Russell Investments Group Ltd. boosted its stake in shares of Inspire Medical Systems by 98.9% during the 1st quarter. Russell Investments Group Ltd. now owns 31,933 shares of the company’s stock worth $6,859,000 after acquiring an additional 15,877 shares in the last quarter. Sei Investments Co. boosted its position in Inspire Medical Systems by 9.7% during the first quarter. Sei Investments Co. now owns 93,666 shares of the company’s stock worth $20,118,000 after purchasing an additional 8,301 shares in the last quarter. Swiss National Bank grew its holdings in Inspire Medical Systems by 0.9% in the first quarter. Swiss National Bank now owns 58,300 shares of the company’s stock valued at $12,522,000 after purchasing an additional 500 shares during the period. Illinois Municipal Retirement Fund increased its position in shares of Inspire Medical Systems by 61.1% in the first quarter. Illinois Municipal Retirement Fund now owns 3,639 shares of the company’s stock valued at $782,000 after buying an additional 1,380 shares in the last quarter. Finally, Lisanti Capital Growth LLC raised its stake in shares of Inspire Medical Systems by 35.3% during the 1st quarter. Lisanti Capital Growth LLC now owns 15,530 shares of the company’s stock worth $3,336,000 after buying an additional 4,050 shares during the period. Institutional investors and hedge funds own 94.91% of the company’s stock.

Inspire Medical Systems Company Profile

Inspire Medical Systems, Inc, a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA.